Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medifast (MED) EBITDA (2016 - 2025)

Medifast's EBITDA history spans 16 years, with the latest figure at -$7.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 1200.56% year-over-year to -$7.8 million; the TTM value through Dec 2025 reached -$14.2 million, down 593.64%, while the annual FY2025 figure was -$14.2 million, 593.85% down from the prior year.
  • EBITDA reached -$7.8 million in Q4 2025 per MED's latest filing, down from -$4.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $61.4 million in Q2 2021 to a low of -$7.9 million in Q2 2024.
  • Average EBITDA over 5 years is $25.8 million, with a median of $29.1 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 124.36% in 2021, then crashed 1200.56% in 2025.
  • A 5-year view of EBITDA shows it stood at $46.8 million in 2021, then plummeted by 30.4% to $32.6 million in 2022, then tumbled by 73.39% to $8.7 million in 2023, then tumbled by 91.83% to $709000.0 in 2024, then plummeted by 1200.56% to -$7.8 million in 2025.
  • Per Business Quant, the three most recent readings for MED's EBITDA are -$7.8 million (Q4 2025), -$4.1 million (Q3 2025), and -$1.1 million (Q2 2025).